Progyny, Inc. (PGNY) Stock Price & How to Invest

Progyny sells a carve-out fertility benefit to self-insured employers. Rather than a dollar cap or a cycle cap, clients buy bundles that Progyny calls Smart Cycles, delivered through a credentialed network of fertility clinics, with an in-house team of care advocates guiding members through treatment. Progyny Rx, the attached specialty pharmacy solution, handles the medications and accounts for roughly a third of revenue. The company launched with five clients in 2016 and had ~604 fertility and family building clients as of June 30, 2026, covering ~7.2 million lives at employers ranging from ~1,000 to ~300,000 employees. It has since extended the same benefits-management model into pregnancy and postpartum, menopause and midlife, leave navigation and parent and child wellbeing, all sold into the same HR buyer.

The financial picture in mid-2026 is a business growing single digits on the headline and low double digits underneath. Q2 2026 revenue was ~$350.5 million, up ~5.3% year over year, or ~11% once you strip out the ~$17.2 million contributed in the prior-year quarter by a very large client that did not renew for 2025. Gross margin widened to ~25.5% from ~23.7%, net income nearly doubled to ~$28.1 million, and the share count has fallen from ~83.4 million to ~77.4 million as two $200 million repurchase programs ran. The stock still fell ~7% on August 7, 2026 to ~$28.10, because third quarter guidance embeds a more pronounced summer lull in member activity. That is the tension worth understanding: an employer benefit with high retention and a real network advantage, priced against the memory of one client departure that erased several points of growth for two years running.

Client concentration is the structural risk: contracts run three years but carry termination options after year one on 30 to 90 days' notice, and the departure of one large client removed ~$48.5 million of 2025 revenue and suppressed reported growth through the first half of 2026. Utilization is not under management's control, and a soft engagement year would flow almost directly to the top line because the recurring population fee is only ~1% of revenue. Gross margin of ~25.5% is thin by software standards because Progyny passes through clinic and pharmacy costs, so an adverse shift in treatment or drug mix compresses operating income faster than revenue implies. Competitively, health plans and pharmacy benefit managers can fold a fertility rider into a contract the employer already signed, and venture-funded specialists compete on price in the same RFPs. Reproductive-health politics adds a further layer, since state-level rulings on embryos and any change to federal IVF coverage rules can reshape both demand and the cost of delivering care.

11 analysts publish price targets on PGNY, averaging $33.82 against a $28.10 price as of August 2026, or +20.4%. The published targets run from $27.00 to $40.00, a moderate spread, and the ratings split 9 buy, 2 hold, 0 sell. Over the last six months there have been 10 raises and 2 cuts among the published actions. A price target is what an analyst published on a date, not a prediction, and sell-side ratings skew positive across the whole market.

Read the full PGNY forecast and price target for the target table, the recent rating actions by firm, and how the consensus has shifted.

We give no verdict on Progyny, Inc.. Both cases are real, which is why the question is contested at all, so here is the strongest version of each.

The case for buying. Client wins and covered lives. Progyny ended Q2 2026 with ~604 fertility and family building clients, up from ~542 a year earlier, and average members of ~7.19 million versus ~6.74 million. The most optimistic published target, $40.00, assumes this works close to its best case.

The case against. Client concentration is the structural risk: contracts run three years but carry termination options after year one on 30 to 90 days' notice, and the departure of one large client removed ~$48.5 million of 2025 revenue and suppressed reported growth through the first half of 2026. The most pessimistic target, $27.00, is roughly what PGNY is worth if this bites instead.

Read the full bull and bear case on PGNY, including what would have to change to break either one. Walnut is not an investment adviser.

A simple financial snapshot. These are approximations and refresh quarterly; for current figures see Progyny, Inc.'s investor relations page or your broker.

• Revenue (TTM): ~$1.31 billion, with FY2025 at ~$1.289 billion and FY2024 at ~$1.167 billion
• Clients and covered lives: ~604 fertility and family building clients as of June 30, 2026 (~542 a year earlier), ~7.2 million covered lives
• Utilization: ~0.56% of all members in Q2 2026 versus ~0.55%, and ~0.85% for the first half versus ~0.82%
• Profitability (TTM): ~$79 million GAAP net income and ~$225 million adjusted EBITDA (~17.5% margin), on ~$201 million of operating cash flow
• FY2026 guidance: revenue of ~$1.360 billion to ~$1.385 billion, GAAP diluted EPS of ~$1.26 to ~$1.32, adjusted diluted EPS of ~$2.04 to ~$2.10
• Market value and balance sheet: ~$2.2 billion market cap at ~$28.10 per share (52-week range ~$16.10 to ~$33.06), ~$237 million in cash and marketable securities, no debt drawn on a ~$200 million revolver

At ~$28 the shares carry roughly 21x to 22x guided GAAP earnings and roughly 13x to 14x guided adjusted earnings, which back out the ~$40 million of first-half stock compensation. Because Progyny passes clinic and pharmacy costs through, price-to-sales of ~1.7x understates the real multiple; enterprise value against ~$322 million of trailing gross profit lands near 6x, and against guided adjusted EBITDA near 8x. Those are levels that price single-digit growth and a repeat of the 2024 client loss rather than a return to the twenty-percent growth of 2021 through 2023.

Other names that sit close to PGNY: same theme, named as a direct competitor, or held beside it in the same funds. Each entry says which. Worth a look if you are thinking about diversification within a thesis rather than concentration on one ticker.

There are three common ways to get PGNY exposure. Buy shares (or fractional shares) directly at any major broker. Hold an ETF that includes it, which spreads the position across many companies. Or build it into a focused thematic portfolio, so PGNY sits alongside other stocks that express the same thesis.

Walnut takes the portfolio route. Describe a thesis where PGNY fits (for example “AI infrastructure” or “dividend-growth large-caps”) and the AI proposes 5 to 6 constituents with target weights. You review the plan and fund it through your own broker when you're ready.

New to this? Start with how to invest in stocks, see how to analyze a stock with AI, or compare the best AI stock analyzers.

Progyny is a cash generative benefits manager whose year is decided by client wins and member utilization rather than by anything management can steer inside a single quarter.

Whether PGNY is worth buying today depends more on your time horizon and what you already hold than on any single call. We walk through valuation, what would have to go right, and the risks in is PGNY a buy or a sell?, and where the stock could go from here in the PGNY stock forecast.

For income investors, whether PGNY pays a dividend and how the payout looks is covered in does PGNY pay a dividend? And to weigh PGNY against a peer, read the full side-by-side comparisons: PGNY vs UNH and PGNY vs ELV.